Halda Therapeutics, founded with a mission to revolutionize precision medicine, focuses on developing innovative treatments for various diseases, particularly cancer. The company leverages a novel therapeutic modality known as RIPTAC (Regulated Intracellular Protein Targeting Chimera), which employs a 'hold-and-kill' mechanism to selectively target and kill cancer cells. By holding two proteins together—one tumor-specific and another essential for cell function—Halda aims to create highly selective and effective cancer therapies.

Notable figures affiliated with Halda Therapeutics include leading scientists and industry experts dedicated to drug innovation. The company has attracted significant interest from investors in the biotech sector, underscoring its potential impact. Key achievements include the development of their RIPTAC platform, which represents a significant advancement in targeted cancer therapy. Halda's pioneering approach has the potential to transform cancer treatment, offering hope for more effective and less toxic therapeutic options.